Company intelligence / Profile preview

Tough Genes

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Tough Genes is a biotechnology company focused on developing next-generation adeno-associated virus (AAV) vectors to improve the safety and efficacy of gene therapies. Founded by gene therapy pioneer Dr. James Wilson, the company leverages advanced engineering to create vectors with enhanced tissue specificity and reduced immunogenicity. Their platform aims to address the primary bottlenecks in the field, including high-dose toxicity and manufacturing scalability. By optimizing the viral capsid and genome, Tough Genes seeks to expand the reach of genetic medicines to a broader range of clinical indications.

Therapeutic areas: Rare Diseases
Modalities: Gene therapy
Industry: Biotech

Beyond the preview

Go deeper on Tough Genes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tough Genes.

Explore the full profile